278 related articles for article (PubMed ID: 25627311)
1. Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects.
Sato M; Kamada Y; Takeda Y; Kida S; Ohara Y; Fujii H; Akita M; Mizutani K; Yoshida Y; Yamada M; Hougaku H; Takehara T; Miyoshi E
Liver Int; 2015 Mar; 35(3):925-35. PubMed ID: 25627311
[TBL] [Abstract][Full Text] [Related]
2. The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease.
Celebi G; Genc H; Gurel H; Sertoglu E; Kara M; Tapan S; Acikel C; Karslioglu Y; Ercin CN; Dogru T
Saudi J Gastroenterol; 2015; 21(3):139-45. PubMed ID: 26021772
[TBL] [Abstract][Full Text] [Related]
3. Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease.
Dogru T; Genc H; Tapan S; Aslan F; Ercin CN; Ors F; Kara M; Sertoglu E; Karslioglu Y; Bagci S; Kurt I; Sonmez A
Clin Endocrinol (Oxf); 2013 May; 78(5):712-7. PubMed ID: 22676641
[TBL] [Abstract][Full Text] [Related]
4. Fetuin A is a Predictor of Liver Fat in Preoperative Patients with Nonalcoholic Fatty Liver Disease.
von Loeffelholz C; Horn P; Birkenfeld AL; Claus RA; Metzing BU; Döcke S; Jahreis G; Heller R; Hoppe S; Stockmann M; Lock JF; Rieger A; Weickert MO; Settmacher U; Rauchfuß F; Pfeiffer AF; Bauer M; Sponholz C
J Invest Surg; 2016 Oct; 29(5):266-74. PubMed ID: 26980291
[TBL] [Abstract][Full Text] [Related]
5. Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose.
Ou HY; Yang YC; Wu HT; Wu JS; Lu FH; Chang CJ
J Clin Endocrinol Metab; 2012 Dec; 97(12):4717-23. PubMed ID: 23066121
[TBL] [Abstract][Full Text] [Related]
6. Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease.
Ebert T; Linder N; Schaudinn A; Busse H; Berger J; Lichtinghagen R; Keim V; Wiegand J; Karlas T
Endocrine; 2017 Nov; 58(2):246-252. PubMed ID: 28914407
[TBL] [Abstract][Full Text] [Related]
7. Serum fetuin A concentration is elevated in children with non-alcoholic fatty liver disease.
Lebensztejn DM; Białokoz-Kalinowska I; Kłusek-Oksiuta M; Tarasów E; Wojtkowska M; Kaczmarski M
Adv Med Sci; 2014 Mar; 59(1):81-4. PubMed ID: 24797980
[TBL] [Abstract][Full Text] [Related]
8. Relationship of serum fetuin-A levels with coronary atherosclerotic burden and NAFLD in patients undergoing elective coronary angiography.
Ballestri S; Meschiari E; Baldelli E; Musumeci FE; Romagnoli D; Trenti T; Zennaro RG; Lonardo A; Loria P
Metab Syndr Relat Disord; 2013 Aug; 11(4):289-95. PubMed ID: 23600632
[TBL] [Abstract][Full Text] [Related]
9. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies.
Haukeland JW; Dahl TB; Yndestad A; Gladhaug IP; Løberg EM; Haaland T; Konopski Z; Wium C; Aasheim ET; Johansen OE; Aukrust P; Halvorsen B; Birkeland KI
Eur J Endocrinol; 2012 Mar; 166(3):503-10. PubMed ID: 22170794
[TBL] [Abstract][Full Text] [Related]
10. APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B.
Ucar F; Sezer S; Ginis Z; Ozturk G; Albayrak A; Basar O; Ekiz F; Coban S; Yuksel O; Armutcu F; Akbal E
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1076-81. PubMed ID: 23510962
[TBL] [Abstract][Full Text] [Related]
11. Serum Fetuin-A levels in obese children with biopsy proven nonalcoholic fatty liver disease.
Pampanini V; Inzaghi E; Germani D; Alterio A; Puglianiello A; Alisi A; Nobili V; Cianfarani S
Nutr Metab Cardiovasc Dis; 2018 Jan; 28(1):71-76. PubMed ID: 29122442
[TBL] [Abstract][Full Text] [Related]
12. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance.
Rametta R; Ruscica M; Dongiovanni P; Macchi C; Fracanzani AL; Steffani L; Fargion S; Magni P; Valenti L
Eur J Clin Invest; 2014 Jul; 44(7):627-33. PubMed ID: 24828988
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease fibrosis score and preclinical vascular damage in morbidly obese patients.
Gentili A; Daviddi G; De Vuono S; Ricci MA; Di Filippo F; Alaeddin A; Mannarino MR; Boni M; Vaudo G; Lupattelli G
Dig Liver Dis; 2016 Aug; 48(8):904-8. PubMed ID: 27160697
[TBL] [Abstract][Full Text] [Related]
14. Serum fetuin-A concentrations are elevated in subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes.
Ou HY; Yang YC; Wu HT; Wu JS; Lu FH; Chang CJ
Clin Endocrinol (Oxf); 2011 Oct; 75(4):450-5. PubMed ID: 21521338
[TBL] [Abstract][Full Text] [Related]
15. Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis.
Cengiz M; Ozenirler S; Kocabiyik M
Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):57-63. PubMed ID: 26513612
[TBL] [Abstract][Full Text] [Related]
16. Endoplasmic reticulum stress induces the expression of fetuin-A to develop insulin resistance.
Ou HY; Wu HT; Hung HC; Yang YC; Wu JS; Chang CJ
Endocrinology; 2012 Jul; 153(7):2974-84. PubMed ID: 22619360
[TBL] [Abstract][Full Text] [Related]
17. Circulating levels of fetuin-A are associated with moderate-severe hepatic steatosis in young adults.
Filardi T; Panimolle F; Tiberti C; Crescioli C; Lenzi A; Pallotta N; Morano S
J Endocrinol Invest; 2021 Jan; 44(1):105-110. PubMed ID: 32350824
[TBL] [Abstract][Full Text] [Related]
18. Association of high alpha2-Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass.
Fiore CE; Celotta G; Politi GG; Di Pino L; Castelli Z; Mangiafico RA; Signorelli SS; Pennisi P
Atherosclerosis; 2007 Nov; 195(1):110-5. PubMed ID: 17010978
[TBL] [Abstract][Full Text] [Related]
19. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology.
Yilmaz Y; Eren F
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):43-46. PubMed ID: 30134384
[TBL] [Abstract][Full Text] [Related]
20. Hepatic insulin resistance in NAFLD: relationship with markers of atherosclerosis and metabolic syndrome components.
Privitera G; Spadaro L; Alagona C; Calanna S; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2016 Jun; 53(3):449-59. PubMed ID: 26496770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
